Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial.

Tassorelli C, Jensen RH, Goadsby PJ, Charles AC, Tepper SJ, Snoer AH, Josiassen MK, Linander CB, Ettrup A, Sperling B, Boneva N

Open source

DOI
10.1016/s1474-4422(25)00065-1
Published
2025 May
Container
The Lancet. Neurology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-25-00065-1,
  title = {Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial.},
  author = {Tassorelli C and Jensen RH and Goadsby PJ and Charles AC and Tepper SJ and Snoer AH and Josiassen MK and Linander CB and Ettrup A and Sperling B and Boneva N},
  year = {2025},
  journal = {The Lancet. Neurology},
  doi = {10.1016/s1474-4422(25)00065-1},
  url = {https://doi.org/10.1016/s1474-4422(25)00065-1}
}

RIS

TY  - JOUR
TI  - Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial.
AU  - Tassorelli C
AU  - Jensen RH
AU  - Goadsby PJ
AU  - Charles AC
AU  - Tepper SJ
AU  - Snoer AH
AU  - Josiassen MK
AU  - Linander CB
AU  - Ettrup A
AU  - Sperling B
AU  - Boneva N
PY  - 2025
JO  - The Lancet. Neurology
DO  - 10.1016/s1474-4422(25)00065-1
UR  - https://doi.org/10.1016/s1474-4422(25)00065-1
ER  - 

APA

C, T., RH, J., PJ, G., AC, C., SJ, T., AH, S., MK, J., CB, L., A, E., B, S., & N, B. (2025). Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(25)00065-1

Source records